Transparency in clinical trials is continually changing, and to stay on top of the news, TrialAssure brings a weekly round-up of some of the key stories surrounding disclosures in clinical trials. This week’s stories are as follows:
EMA scaling back transparency plans – The BMJ
Policy 0043 – a policy which gave access to EMA’s archived documents – is now limited to use by European Union citizens only. Additionally, excessive workload is said to be the cause for cutbacks, including the suspensions of publishing new data packages as a part of Policy 0070. The article states that this is a major interruption of the important transparency initiatives that need to be continued.
Read the full article here.
The Open Science movement champions transparency – The Scientific American
The Open Science movement is a belief that data should be freely available for all to study, making science more “democratic and accessible.” The article presents an in-depth case regarding the need for open data and who benefits.
Read the full piece here.
Transparency experts convene in Philadelphia – Twitter
EXL held their 2nd Disclosure and Transparency for Clinical Data Summit at The Inn at Penn in Philadelphia, PA on August 13-14, 2018. The event was packed with thought-provoking discussion from some of the top minds in transparency. During his talk, Mohamad Zahreddine, CIO, TrialAssure, said “I see the future of transparency to involve two-way communication with registries and sponsors, as well as a potential harmonization of global registry standards.”
See a full recap of the event in social posts here.